Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040

Dow Jones

2025/10/03

By Adriano Marchese

Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.

Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.

Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.

Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.

Dr. Reddy's wasn't readily available for comment.

Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

October 03, 2025 08:42 ET (12:42 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572507271"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572507271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572507271?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572507271","market":"hk","top_or_hot":-1,"title":"Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dr. Reddy's Laboratories won't market a generic version of Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' cholesterol drugs after a reaching a settlement. \n</p>\n<p>\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n</p>\n<p>\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n</p>\n<p>\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n</p>\n<p>\n  Dr. Reddy's wasn't readily available for comment. \n</p>\n<p>\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 03, 2025 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion Therapeutics Blocks Dr. Reddy's Generic Version of Cholesterol Drugs Until 2040\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-03 20:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Dr. Reddy's Laboratories won't market a generic version of Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' cholesterol drugs after a reaching a settlement. \n</p>\n<p>\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n</p>\n<p>\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n</p>\n<p>\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n</p>\n<p>\n  Dr. Reddy's wasn't readily available for comment. \n</p>\n<p>\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 03, 2025 08:42 ET (12:42 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4596","symbol_name":"哈里斯概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572507271","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572507271","pubTimestamp":1759495320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement.Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet.Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults.Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040.Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4596":"哈里斯概念","BK4007":"制药","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC","ESPR":"Esperion Therapeutics Inc.","BK4523":"印度概念","RDY":"如瑞迪博士","BK4557":"大麻股","BK4532":"文艺复兴科技持仓"},"translate_title":"Esperion Therapeutics在2040年之前阻止Reddy博士的胆固醇药物仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5,"RDY":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Dr. Reddy's Laboratories won't market a generic version of Esperion Therapeutics' cholesterol drugs after a reaching a settlement. \n\n\n  Esperion Therapeutics, a pharmaceutical company, said Friday that it has settled with India-based pharmaceutical company Dr. Reddy's which was seeking approval to market its own generic versions of its Nexletol and Nexlizet. \n\n\n  Nexletol and Nexlizet are prescription medications used to lower LDL cholesterol, known as the bad cholesterol, and reduce the risk of heart-related issues in adults. \n\n\n  Dr. Reddy's had made an abbreviated new drug application for its generic version of the drugs, but following the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either in the U.S. before 2040. \n\n\n  Dr. Reddy's wasn't readily available for comment. \n\n\n  Earlier this year, Esperion said it had reached settlement agreements with a number of other pharmaceuticals regarding generic versions of Nexletol. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 03, 2025 08:42 ET (12:42 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}